Lilly, Merck and Valeant feel sting of DOJ drug pricing probe

Big Pharma has been dealing with government pushback over drug pricing, with Valeant ($VRX) coming under the most scrutiny after jacking up the prices for two of its newly purchased cardio drugs. Now, Eli Lilly ($LLY) and Merck ($MRK) are joining the Canadian pharma in the hot seat as the U.S. Department of Justice probes the companies over how they report prices to government-funded drug programs. More from FiercePharma